EUCTR2011-001815-29-NL进行中（未招募）不适用
Chemopreventive effects of mesalazine in patients at high risk of recurrent (nonfamilial) colorectal adenomas - mesalazine effects in sporadic colorectal adenoma patients
MC Utrecht0 个研究点开始时间: 2011年8月22日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- having undergone complete colonoscopy with polypectomy, within 6 months of study entry, for removal of at least 2 colorectal adenomas, irrespective of size, and/or 1 colorectal adenoma with at least one of the following features: diameter of at least 1 cm, proximal localization, high-grade dysplasia or villous aspects.
- •- age 50-75 years
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 28
排除标准
- •- inflammatory bowel disease
- •- familial colorectal cancer syndrome
- •- history of colorectal carcinoma
- •- history of surgery to the large bowel (except appendectomy)
- •- chronic renal insufficiency
- •- chronic hepatic insufficiency
- •- allergy to salicylates
- •- diabetes mellitus
- •- coagulation disorder or anticoagulant use, which cannot be temporarily discontinued
- •- regular intake of one or more of the following immunosuppressants: thiopurines, methotrexate or cyclosporin
- •- prescription use of aspirin (high- and low-dose) and other NSAIDs
研究者
相似试验
已完成
2 期
Chemopreventive effects of mesalazine in patients at high risk of recurrent (nonfamilial) colorectal adenomassporadic colorectal adenomasporadic colorectal adenomatous polyps1001793410017987NL-OMON38274niversitair Medisch Centrum Utrecht68
已完成
2 期
Mesalazine Effects in Sporadic Colorectal Adenoma PatientsSporadic Colorectal AdenomaNCT01894685UMC Utrecht74
进行中（未招募）
不适用
Efficacy of mesalazine in the long term prevention of diverticulitis relapses.Randomised study, double blind, controlled vs placebo.EUCTR2005-001459-39-ITSOFAR SPA
进行中（未招募）
不适用
Evaluation of the role of mesalazine in the treatment of diverticular disease of the colon and irritable colon syndrome: A randomised double blind placebo controlled clinical study - NDIrritable bowel Syndrome Diverticular disease of the colonMedDRA version: 9.1Level: LLTClassification code 10009993MedDRA version: 9.1Level: LLTClassification code 10023004EUCTR2008-004228-22-ITSOFAR SPA
进行中（未招募）
1 期
Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D). - Mesalazine for the treatment of IBS-DDiarrhoea-predominant irritable bowel syndromeMedDRA version: 14.0 Level: LLT Classification code 10060849 Term: Diarrhoea predominant irritable bowel syndrome System Organ Class: 10017947 - Gastrointestinal disordersEUCTR2010-018340-14-GBniversity of Nottingham136